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Rasch analysis of responses from
community-dwelling adults with
neuropathic pain
Tara L. Packham1*, Joseph C. Cappelleri2, Alesia Sadosky3, Joy C. MacDermid1,4 and Florian Brunner5
Abstract
Background: painDETECT (PD-Q) is a self-reported assessment of pain qualities developed as a screening tool for
pain of neuropathic origin. Rasch analysis is a strategy for examining the measurement characteristics of a scale
using a form of item response theory. We conducted a Rasch analysis to consider if the scoring and measurement
properties of PD-Q would support its use as an outcome measure.
Methods: Rasch analysis was conducted on PD-Q scores drawn from a cross-sectional study of the burden and
costs of NeP. The analysis followed an iterative process based on recommendations in the literature, including
examination of sequential scoring categories, unidimensionality, reliability and differential item function. Data from
624 persons with a diagnosis of painful diabetic polyneuropathy, small fibre neuropathy, and neuropathic pain
associated with chronic low back pain, spinal cord injury, HIV-related pain, or chronic post-surgical pain was used
for this analysis.
Results: PD-Q demonstrated fit to the Rasch model after adjustments of scoring categories for four items, and
omission of the time course and radiating questions. The resulting seven-item scale of pain qualities demonstrated
good reliability with a person-separation index of 0.79. No scoring bias (differential item functioning) was found for
this version.
Conclusions: Rasch modelling suggests the seven pain-qualities items from PD-Q may be used as an outcome
measure. Further research is required to confirm validity and responsiveness in a clinical setting.
Keywords: Neuropathic pain, PainDETECT, Outcome measurement, Rasch analysis
Background
Pain is not only a multi-faceted sensory and emotional
experience, but can present in different forms [1]. Noci-
ceptive pain is considered to be the protective warning
system to signal or avoid tissue damage [2], while neuro-
pathic pain (NeP) represents a persistent pain resulting
from damage to the nervous system [3]. PainDETECT
(PD-Q) is a 9-item self-report screening questionnaire
developed to detect NeP in conditions like chronic low
back pain [4]. PD-Q measures 7 aspects of the quality of
the pain experienced, the chronological pattern (time
course), and whether or not the pain radiates. It is scored
from 0 to 38, with total scores of less than 12 considered
to represent nociceptive pain, 13–18 possible NeP, and
>19 representing >90% likelihood of NeP (see Additional
file 1: Supplementary Figure A for a sample of the form
and associated scoring). The developers undertook clas-
sic psychometric testing in 392 persons with varied con-
ditions including low back pain, post-herpetic neuralgia,
painful polyneuropathy, osteoarthritis, visceral pain, and
inflammatory arthropathies. They reported a sensitivity
of 84% and specificity of 84% for NeP compared to a ref-
erence standard based on expert examination, and ro-
bust internal consistency amongst the 7 pain quality
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items. [4] The US English version of this tool has been
employed to evaluate populations including osteoarth-
ritis [5, 6], rheumatoid arthritis [7, 8], amyotrophic lat-
eral sclerosis [9], neck and upper limb pain [10], and a
cross-section of NeP conditions [11, 12].
Rasch analysis
Rasch analysis is an approach aimed at understanding
the measurement characteristics of an assessment. A key
advantage of this type of analysis is if data produced by a
measure like PD-Q fit the Rasch model, the ordinal scale
measurements of individual test items (such as PD-Q’s
Never to Very Strongly ratings) can be converted into
interval-level scaling like 0 to 5 that can be credibly
summed into total scores, with desirable measurement
properties [13, 14]. Another key premise of Rasch mod-
elling is invariance of the model across samples: mean-
ing a Rasch-validated tool can be expected to measure
the same way regardless of the population being studied
[15, 16] because the assessment itself is validated, not the
measurement characteristics for a specific population.
In contrast to traditional item response theory (IRT),
Rasch analysis evaluates measurement characteristics
using probability estimates, describing items as easy or
difficult relative to the ability of the respondents [16–
18]. For example, an item would be considered ‘easy’ if
most respondents, even those with severe disease scored
favorably on the item, and ‘difficult’ or ‘severe’ if only
persons with mild disease scored favorably on the item.
Persons and items are “fit” to this fixed model rather
than developing a model around the data points [13].
The average difficulty/severity of the items is typically
set to zero as a reference for this fitting process, and
both item-level (difficulty or severity) and person-level
estimates on the construct attempting to be measured
(e.g., level of NeP) are standardized to Z scores [19]. The
final key concept in Rasch theory is unidimensionality;
that is, each scale or subscale represents a single charac-
teristic or construct.
Rasch analysis and painDETECT
The PD-Q utilizes a 0–5 adjectival scoring system for
pain qualities instead of the dichotomous present/absent
format often seen in screening tools. Since multi-level
scoring is preferable for measuring health outcomes:
[20] that is, longitudinally measuring change over time,
it is possible PD-Q could serve this purpose [11]. If the
current 0–5 scaling could be shown to demonstrate
interval-level properties, or be transformed to provide
interval-level measurement, it could support the use of
the PD-Q as an outcome measure.
Moreton et al [5] conducted a Rasch analysis of the
PD-Q on 135 subjects with osteoarthritis (OA) to con-
sider its potential as an outcome measure and advocated
omission of the pain course item for optimal model fit
[5]. The remaining items (7 pain qualities plus radiating)
demonstrated fit to the model, but the analysis of a sin-
gle population with largely nociceptive pain suggested
PD-Q may lack the precision to measure outcomes in
persons with few or no features of NeP [5]. However, it
is important to note participants were not physician-
assessed to confirm the diagnosis of NeP, which was
self-reported using PD-Q in 27% of the sample. There-
fore, further Rasch analysis of PD-Q is warranted using
a relatively large heterogeneous population with a range
of physician-confirmed NeP diagnoses (including but
not restricted to OA) in order to examine differential
item function or (potential measurement bias) by diag-
nosis. The purpose of this study is to use Rasch analysis
to assess whether painDETECT demonstrates measure-
ment properties consistent with an outcome measure.
Methods
Participants
This study is a secondary data analysis of a previously
published cross-sectional survey of the burden and costs
for 624 patients with NeP [21, 22]. The NeP conditions
examined in the study were painful diabetic peripheral
neuropathy (pDPN), chronic lower back pain with NeP,
spinal cord injury related NeP (SCI-NeP), small fiber
neuropathy, human immunodeficiency virus related NeP,
and post-trauma post-surgical pain.
Variables of interest
Data from the NeP survey were compiled in Excel for
demographic examination and imported to RUMM2030
version 5.1 (RUMM Laboratory Pty Ltd: Perth,
Australia) for Rasch analysis. Demographic data included
age, sex, and NeP diagnostic group (see Table 1); other
person-level characteristics included in the analysis were
summary scores from the physical and mental compo-
nents scales (PCS and MCS) of the SF-12 [23] and pain
severity and pain interference scores from the Brief Pain
Inventory (BPI) [24, 25]. Variable selection originated
from a rank-ordering exercise of six external experts in
NeP from a network of clinicians and scientists working
on the development of a Core Outcome Measures for
complex regional PAin syndrome Clinical STudies
(COMPACT) [26]. Detailed and accessible description of
the Rasch model and the application to scale analysis is pub-
lished elsewhere for the interested reader [15–17, 27, 28].
Sample size for Rasch analysis can be calculated fol-
lowing Linacre’s rule-of-thumb formula of n = 20 x num-
ber of items or n = 250, whichever is larger [29]. Thus,
for the 9 item PD-Q, a sample of 250 would be the mini-
mum required to support the accuracy of estimates of
item difficulty or severity [27, 29].
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Analysis plan
Statistical analyses mirrored those recommended by
Tennant et al [19], incorporating the iterative step test-
ing of Lundgren-Nilsson and Tennant [27], which in-
cluded: 1) response distribution, 2) class interval
distribution, 3) unidimensionality, 4) thresholds (includ-
ing rescoring when required), 5) individual person fit, 6)
local dependency, 7) differential item functioning (DIF),
and 8) item fit to the scale. Unidimensionality is con-
firmed by a two-step process: 1) principal components
factor analysis to identify the positive and negatively
loading patterns of the items, and then 2) subsequent t-
testing of the cluster of positively loading items against
the negatively loading items. [19, 30] The theoretical
basis of this strategy is if the scale is truly unidimen-
sional, the groups will be have a positive t-test at p =
0.05 [19]. After these examinations, deletion of mis-
fitting items was considered and the balance of statistical
scale robustness and clinically important items were
weighed [27]. Bonferroni corrections for multiple ana-
lyses were used when appropriate.
The person separation index (PSI) was calculated to
estimate how many comparative groups could be deter-
mined within the sample, and whether the scale was suf-
ficiently robust for group or individual comparisons [19,
31]. The PSI is also used as an indicator of measurement
reliability. Finally, the person-item distribution was plot-
ted to consider how well the persons in the sample
match traits being measured by the scale, also known as
the targeting of the scale to the sample. A more detailed
summary of analyses and associated statistical tests can
be found in Additional file 1: Supplemental Table A.
Results
Demographics
Six hundred and twenty-four data files from a published
NeP burden of illness study were available for Rasch
modelling [22]. Men accounted for 55.6% of the sample
and mean age was 55.4 years (Table 1).
Table 1 Demographics (including description and coding for
person variables). N.B. Means presented are from raw scores, not
categorized values. Key: NeP = neuropathic pain, SF = short form,
PCS = Physical components summary, MCS = Mental
components summary, BPI = Brief Pain Inventory
Person Variable Coding N** (%)
Age
Sample mean age =
55.4 years
Total N = 624
Under 20 1 (0.2)
20–29 years 24 (3.8)
30–39 years 43 (6.9)
40–49 years 134
(21.5)
50–59 years 199
(31.9)
60–69 years 122
(19.6)
70–79 years 73 (11.7)
80 plus 28 (4.5)
Sex Male 347
(55.6)
Female 277
(44.4)
NeP Diagnosis Chronic low back pain 103
(16.5)
Post-Diabetic peripheral
neuralgia
100
(16.0)
HIV related pain 103
(16,5)
Chronic post-surgical pain 106
(17.0)
Small fiber neuropathy 110
(17.6)
Spinal cord injury 97 (15.5)
SF12 PCS
Mean PCS = 31
(100 = perfect health)
0–19 61 (10.0)
20–39 446
(73.0)
40–59 102
(16.7)
60–79 2 (0.3)
80–100 0
SF12 MCS
Mean MCS = 42.5
(100 = perfect health)
0–19 22 (3.6)
20–39 241
(39.4)
40–59 288
(47.1)
60–79 60 (9.8)
80–100 0
BPI pain severity
Mean =5.2
0–3 Mild 111
(18.1)
4–6 Moderate 297
(48.4)
7–10 Severe 206
(33.6)
Table 1 Demographics (including description and coding for
person variables). N.B. Means presented are from raw scores, not
categorized values. Key: NeP = neuropathic pain, SF = short form,
PCS = Physical components summary, MCS = Mental
components summary, BPI = Brief Pain Inventory (Continued)
BPI pain interference
Mean = 5.6
0–3 Mild 163
(26.2)
4–6 Moderate 244
(39.2)
7–10 Severe 216
(34.7)
** some total results for individual tests may not add up to 624 if data from a
particular scale were missing; percentages are reported for the total number
of available data sets
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Analysis of 9 item PD-Q
Distribution of responses
All levels of scoring were used for all items; a score of 0
on the tingling item was the least frequently endorsed,
with only 28 of the 620 persons completing the item
scoring themselves as ‘never’ for experiencing tingling or
prickling sensations in the area of their pain. Further-
more, 400 persons (64%) described their pain as radiat-
ing (see Additional file 1: Supplementary Table B for the
full listing of response distributions). Review of the class
interval distribution using a 10-class interval structure
recommended by RUMM2030 on the basis of sample
size demonstrated high variability across the 10 class in-
tervals. Alternate class interval structures were thus ex-
plored, and a 4 class interval structure was chosen,
yielding more balanced groupings of 142–162 persons
per item distributed across the class intervals.
Thresholds
A threshold indicates the point where there is a 50/50
probability of respondents choosing between any two
adjacent score categories; thus the number of thresholds
is always one less than the number of score categories.
Initially, five items on the PD-Q (burning, tingling,
electric-shock, numbness and time course) presented dis-
ordered thresholds by Rasch analysis. For example, re-
sponses to these questions on pain quality did not follow
the same progression (from low scores to high scores) as
the progression of severity of the person scoring (from
low levels to high levels of NeP). This point is illustrated
in Fig. 1a, where the probability of scoring a 0 out of 5
on the burning item overlapped the probability of scor-
ing 1/5. Therefore, items were re-scored by collapsing
response categories based on the category probability
curves (see Fig. 1a & b for graphs representing burning)
until the thresholds demonstrated sequential levels of se-
verity. This resulted in a decrease in the number of re-
sponse categories from 6 to 5 for the burning, tingling,
electric shock, and numbness items. The time course item
was rescored to combine pain attacks with and without
pain between attacks. Refer to Table 2 for an illustration
of how the scoring categories were collapsed for each
disordered item.
Fit to the rasch model
Once the thresholds were re-scored, initial fit analysis of
PD-Q to the Rasch model revealed a significant chi-
square value for item-trait interaction [χ2(27) = 84.3 p
<0.000], suggesting when considered as a whole, the PD-
Q did not fit the Rasch model. Therefore we proceeded
to look at each aspect of fit to identify where the misfit
was coming from, and if it could be addressed in the
model.
Individual person fit
Relative to total PD-Q score, one case was designated as
extreme (scoring far lower than would be expected), and
was thus excluded from further analyses. Overall person
fit statistics had a mean of Z = 0.06, suggesting the aver-
age scores were very close to what was expected with an
acceptable SD = 0.83 (see Additional file 1: Supplemen-
tary Table A). Examination of the person-item threshold
distributions for the total PD-Q showed statistically sig-
nificant differences in NeP based on sex, age, PCS and
MCS scores, BPI pain severity, and BPI pain interference
(p <0.01 for all) but not NeP diagnosis (p = 0.09).
Response dependency
Analysis of PD-Q item residuals demonstrated high cor-
relation between the burning and tingling items which
may be the source of misfit to the Rasch model. Proced-
urally, it is recommended these items be treated as a sin-
gle unit or testlet [32], during scoring calculations but
not during administration of the assessment to the pa-
tient; [19] therefore burning and tingling were always
considered together in all future analyses of overall fit.
a) before rescoring b) after rescoring
Fig. 1 Category probability curves for the burning item. a before rescoring (b) after rescoring
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Differential item function
Differential item function describes the risk of systematic
bias (uniform DIF) or random bias (non-uniform DIF).
In this analysis, 4 PD-Q items showed uniform DIF. The
time course was scored differently on the basis of age [p
= 0.001] and BPI severity [p <0.001] and the radiating,
tingling and pressure items were scored differently on
the basis of NeP diagnosis [p <0.001 to p = 0.002]. For
example, the DIF by NeP diagnosis in subjects with
pDPN consistently scored lower than expected on the
tingling item, while persons with SCI-NeP scored con-
sistently higher than expected. It was interesting to note
that despite no evidence of DIF on the basis of sex,
the average PD-Q score was lower for men than for
women when comparing the two groups (F1,617 = 8.32,
p = 0.004): see Fig. 2 for a visual representation of the
converted scores. In clinical terms, this suggests
women in the sample truly had higher levels of pain
than men, and did not just score themselves higher
on the questionnaire.
Individual item fit
Individual items were reviewed for acceptable fit resid-
uals of less than + 2.5 [19]. Of all items in the PD-Q, the
time course item was flagged as not fitting with a fit re-
sidual value = +8.5, along with the radiating item with a
fit residual of +3.2.
Scale and item re-appraisal
Because the time course and radiating items had un-
acceptably high fit residuals [19] which could influence
other analyses (as seen in DIF), we excluded them from
future iterations. This left the seven pain quality items as
had been considered by other authors [4, 12]. After these
revisions of the scale, it was necessary to recheck class
interval distribution and unidimensionality indicators
[13] for this 7-item outcome measure iteration.
Analysis of an 7-item PD-Q outcome measure
With burning and tingling treated as a testlet, this 7 item
PD-Q demonstrated fit to the Rasch model with item-
trait interaction statistics of χ2 (12) = 20.4, p = 0.06 over
three class intervals for ideal balance. This non-
significant chi-square value indicates no difference, or
unidimensionality. However, further exploration of the
scale fit revealed DIF by NeP diagnosis for both the
burning/tingling testlet and the pressure item. We there-
fore elected to combine the burning, tingling, and pres-
sure items as a background ‘subtest’ to see if this DIF
would cancel out across the scale as long as all 3 of these
items were included on the scale [19]. This iteration
Table 2 Rescoring Key
Item Original Scoring 0 1 2 3 4 5
Burning Re-scored 0 1 1 2 3 4
Tingling Re-scored 0 1 1 2 3 4
Electric Shock Re-scored 0 1 1 2 3 4
Temperature Re-scored 0 1 1 2 3 4
Time course Original scoring 0 1 2 3
Re-scored 0 1 2 2
Fig. 2 Person-Item Map grouped by sex. Key for Fig. 2: These dual histograms illustrated the relationship of the severity of NeP in the
respondents (top) to the difficulty of the items (bottom). The logits scale on the x-axes of the graphs represents a standardized score where the
mean severity or difficulty is set to 0, and one logit = one SD. The y-axis of the top histogram shows the probability of attaining the standardized
score if you are a male vs. female; while the lower histogram shows the probability of endorsing a given score for a particular item
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produced item-trait interaction statistics of χ2 (10) =
16.9, p = 0.08 over 3 class intervals, again favoring unidi-
mensionality. The PSI, an indicator of reliability, was
0.79, indicating sufficient reliability for group-level com-
parisons [31].
Person-item distribution
Person-item distribution is a graphical representation of
how well the difficulty/severity of the items match the
extent or level of the concept of interest (e.g. NeP) in
the subjects. Figure 3 illustrates that few persons (repre-
sented by bars in the top histogram) fell outside the
range of severity measured by the PD-Q items (repre-
sented by the bars in the bottom histogram). Analysis of
variance on the standardized (Z) scores by NeP diagnosis
(F(5) = 2.02, p = 0.07) indicated no difference in mean
PD-Q scores between diagnostic groups.
Unidimensionality
Analysis of the 7 item PD-Q met the unidimensionality cri-
terion, as indicated by the proportion of tests finding a dif-
ference found between split halves of the scale; this was less
than 5% (p = 0.028) [30]. This procedure partitions the scale
items using factor analysis into positively and negatively
loading items, and then t-tests these 2 item groups for each
person to ensure they are not different, supporting the hy-
pothesis all items are measuring a single trait [32]. See
Table 3 for a summary of all fit criteria for both the original
9 item and proposed 7item outcome measure version of
PD-Q. See also Additional file 1: Supplementary Figure A
for the item map of the final 7-item version.
Discussion
Summary of findings
We conducted a Rasch analysis of PD-Q to evaluate its
measurement properties as an outcome measure for
possible use research and clinical practice.
Results in light of the existing literature
A Rasch analysis of this tool was completed previously
in a more homogeneous population: [5] the results of
our study, based on physician-confirmed diagnosis of
one of 6 NeP conditions, further demonstrate support
for use of PD-Q as an outcome measure.
Despite the dataset having more men than women (ra-
tio 1.25:1), no DIF was found based on sex. However,
women achieved higher standardized scores than men
on average, (Fig. 2), suggesting they had higher levels of
NeP, which aligns with known population trends in
chronic pain [33, 34].
We were able to demonstrate a 7-item version of the
PD-Q has the potential for use as an outcome measure
for NeP qualities, as it was able to fit the Rasch model
by representing a single construct (is unidimensional);
thus also supporting the Rasch assumption of invariance,
or universal measurement properties across populations.
Additionally, invariance is further supported by the lack
of differences (p = 0.07) seen among NeP diagnoses in
person-item thresholds. Further, it reflects factor analysis
Fig. 3 Person-Item threshold map. Key for Fig. 3: These dual histograms illustrated the relationship of the severity of NeP in the respondents (top)
to the difficulty of the items (bottom). The logits scale on the x-axes of the graphs represents a standardized score where the mean severity or
difficulty is set to 0, and one logit = one SD. The y-axis of the top histogram shows the distribution of standardized scores while the lower histo-
gram shows the probability of endorsing a given score for a particular item
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presented by both the original developers of the tool
which showed all 7 pain qualities loading on a single fac-
tor [4] and previous analysis of this data set supporting
good internal consistency of a 7-item PD-Q [12].
In the Rasch paradigm, reliability is represented by the
person-separation index. Our value of 0.79 fell into the
‘Good’ range [19]. In contrast, Moreton et al [5] re-
ported better discriminative function as demonstrated
by a PSI value of 0.83 [31] for their 8-item iteration of
PD-Q in a potentially underpowered sample.
While our study replicated the findings of Moreton et
al [5] in excluding the time course item and identifica-
tion of local dependency in the burning and tingling
items, there is an important difference. Their study ex-
amined PD-Q in a population of persons with knee OA,
reporting 27% of the group (total n = 192) as having
likely NeP; scores ranged from 8 to 18 with an average
score of 13 (out of a maximum score of 38). However,
the identification of NeP was based entirely on self-
report measures, and was not confirmed by physician
diagnosis. In contrast, our population of 624 persons all
had physician confirmed diagnoses of NeP with an aver-
age PD-Q score of 20.4 (range 1–37). Accordingly, Mor-
eton et al [5] reported PD-Q was not ideally targeted to
their sample of persons with largely nociceptive pain
resulting from OA, while our results, based on a larger
sample and broader range of scores, demonstrated excel-
lent targeting of the PD-Q items across the range of
NeP severity represented in our population (see Fig. 3).
Fit challenges and implications for practice
Because PD-Q was developed as a NeP screening tool
and not an outcome measure, we anticipated a lack of fit
to the Rasch model in its current form. In fitting the
data to the Rasch model, the ordering of categories on
certain items did not reflect corresponding increases in
the amount NeP qualities the items were intended to
measure: thus it was necessary to collapse the scoring
categories on five of the original nine items. This rescor-
ing procedure corrected all disordered pain quality
items, suggesting respondents had trouble distinguishing
between ‘hardly noticed’ and ‘slightly’. In other words,
the probability that persons with similar amounts of
NeP would choose one description or score over an-
other, was not predictable.
Overall, our results suggest a 7-item PD-Q may be ap-
propriate for comparison of outcomes across popula-
tions, with rescoring of the burning, tingling, electric
shock and numbness items. Scoring of the Rasch-
endorsed format would potentially alter the current total
score of 38 for 9 items to 31 for 7 items. This allows
representation of the ordinal responses of the PD-Q pain
quality items as a linear scale [35].
Implications for clinical practice
Rasch analysis suggested exclusion of the pictorial time
course and dichotomous radiating item from summed
scores. This in no way suggests altering the current 9
item form for its validated use as a screening tool for
NeP, yet suggests they may not be as important when
tracking outcomes of the PD-Q (i.e., NeP characteristics
over time). Further research should seek to replicate
these findings and consider opportunities to develop a
Rasch scoring conversion table for easy transformation
of clinically derived ordinal PD-Q scores from the ori-
ginal questionnaire to interval level scores to support ac-
curate longitudinal monitoring to inform clinical care
and research.
Implications for research
Study limitations
It is not known if there is selection bias inherent in
the initial data collection for the NeP survey that
would influence PD-Q scores. A potential bias arises
from the restrictions of the RUMM2030 software,
which allows only 7 person-level factor to be used to
describe and categorize the participants. The decision
of which factors to include was made by the research
team, and may have restricted the opportunity to dis-
cover DIF for PD-Q items related to other important
population characteristics. However, our decisions
were informed by a consensus exercise developed
from a core measurement set for clinical trials in
other pain conditions [26].
While the sample size of 624 NeP subjects was suffi-
cient for analysis, there is a risk this larger sample is
powered to find very small differences, making the target
of a non-significant chi-square value for item-trait inter-
action increasingly stringent.
Conclusion
The Rasch model supported the acceptance of a shorter
7-item pain quality outcomes measure, excluding the
time course and radiating items from the original meas-
ure. This outcome measure conversion of PD-Q may
Table 3 Summary statistics for all analyses
Unidimensionality Item location Person location Item fit residual Person fit residual Item Trait Interaction PSI
9 item PD-Q (original) p = 0.065 95%CI 0.048–0.082 Z = 0.00 SD = 0.37 Z = 0.14 SD = 0.69 Z = 0.77 SD = 3.65** Z = -0.28 SD = 1.26** χ2 (27) = 104.8 p <0.000** 0.77
7 item PD-Q p = 0.028 95%CI 0.011–0.045 Z = 0.00 SD = 0.34 Z = -0.11 SD = 0.99 Z = 0.36 SD = 3.39** Z = -0.39 SD = 1.20** χ2 (10) = 16.78, p = 0.079 0.79
** denotes results which demonstrate misfit
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prove useful for clinicians who wish to accomplish the
dual goal of screening for NeP at baseline, and tracking
changes in pain qualities over time; the dual purpose
could also reduce the overall burden of measurement in
clinical trials. Future research is warranted to confirm
the validity and responsiveness of this Rasch-informed
7-item outcome measure in a clinical setting.
Additional file
Additional file 1: Table SA. Analysis plan summary and Rasch
definitions. Table SB. Response distribution. Figure SA. Item map.
(DOCX 30 kb)
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